GlassScriptPhysician profile
Emma Martin
NPI 1063042075
$5,355.08
in general payments reported to CMS, 2019-2025
23 companies · $755 in 2025
The $755 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,226 · 2022: $1,362 · 2023: $1,293 · 2024: $719 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247 · Education: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.04 |
| Education | $519.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.42 | 2021-2025 | |
| Janssen Biotech, INC. | $889.64 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $755.54 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Merz North America, INC. | $523.95 | 2021-2025 | Xeomin |
| Regeneron Healthcare Solutions, INC. | $387.91 | 2021-2024 | Dupixent |
| Lilly USA, LLC | $314.97 | 2021-2024 | Taltz, Olumiant |
| Galderma Laboratories, L.P. | $228.56 | 2021-2025 | Aklief, Twyneo, Oracea |
| Novartis Pharmaceuticals Corporation | $212.28 | 2021-2025 | |
| Genzyme Corporation | $170.15 | 2022-2025 | |
| Ucb, INC. | $164.24 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $144.25 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $138.16 | 2022-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.79 | 2021-2024 | Arazlo, Siliq, Targretin |
| Vyne Pharmaceuticals INC. | $76.26 | 2021 | |
| Journey Medical Corporation | $61.09 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $41.67 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $30.89 | 2025 | |
| Xeris Pharmaceuticals, INC. | $23.92 | 2025 | Gvoke Hypopen |
| Incyte Corporation | $21.83 | 2023 | Opzelura |
| Si-Bone, INC. | $20.68 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.63 | 2025 | Spevigo |
| Almirall LLC | $18.98 | 2023 | Klisyri |
| Fidia Pharma USA INC. | $15.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.